CeriBell (NASDAQ:CBLL) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of CeriBell (NASDAQ:CBLL) have earned a consensus recommendation of “Buy” from the six brokerages that are covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have covered the stock in the last year is $32.60.

CBLL has been the subject of a number of recent research reports. Canaccord Genuity Group began coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $30.00 price objective for the company. Canaccord Genuity Group raised their target price on shares of CeriBell from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. JPMorgan Chase & Co. began coverage on shares of CeriBell in a research report on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 price target for the company. TD Cowen raised their price objective on shares of CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Finally, Bank of America began coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued a “buy” rating and a $32.00 target price for the company.

CeriBell Stock Up 4.4 %

Shares of CBLL opened at $21.04 on Friday. The company’s fifty day moving average is $26.29. CeriBell has a 1-year low of $18.69 and a 1-year high of $32.75.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($1.03). The business had revenue of $17.20 million during the quarter, compared to analyst estimates of $17.06 million. Sell-side analysts expect that CeriBell will post -2.46 earnings per share for the current year.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.